Market size? growth rates, expectations? etc etc... throw us a bone here...
Meanwhile our friends at NAB are making a good living buying large chunks of this firm and then on lending these shares out to our shorting friends at Macbank and co.
-----
AXIRON NOW AVAILABLE IN BRAZIL
Acrux (ASX: ACR) today confirmed that Axiron® is now being distributed by Eli Lilly and Company in Brazil for testosterone replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). The product is being sold in Brazil under the trademark Axeron.
Acrux Executive Chairman Ross Dobinson commented “We are pleased that Lilly has achieved another milestone in the international commercialisation of Axiron, which is already available to patients in the United States, Australia and Canada and which also recently received approval in Germany.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.366M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 883823 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 500697 | 1 |
View Market Depth
| Last trade - 16.21pm 30/07/2025 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable